cobas® liat system

IVD For in vitro diagnostic use.

Fast, reliable syndromic testing for informed therapeutic decisions

The Roche cobas® liat system, gold-standard PCR technology at the Point of Care.

When patients need a fast diagnosis and treatment decision, they count on you to have the right answers, at the right time, wherever you need them. With the cobas® liat system, you can bring gold-standard PCR technology1 directly to any Point of Care setting. From the emergency room to clinics, it enables quick detection of SARS-CoV-2, influenza A/B, respiratory syncytial virus (RSV), strep A, Clostridioides difficile (C. diff), Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), and more to come.

The cobas® liat system is compact, user-friendly, and fast—delivering accurate results5 by the time your patient’s appointment ends. It automates complex PCR processes, providing quick, single-sample analysis without support from a skilled technician. With no operator interpretation required, you can confidently rely on results delivered in 20 minutes or less.2-9

Enhance your control of near-patient testing by integrating cobas® liat system with navify® POC digital solutions. You can now streamline your workflow with centralized device and data management while enabling informed decisions right at the Point of Care that help improve clinician outcomes and reduce disease transmission.

Three easy steps to get the answers you need

The Roche cobas® liat system with patient sample being added to the assay tube  via transfer pipette.

1. Sample

Easily add your patient sample to the assay tube using the provided transfer pipette.

Read More
The Roche cobas® liat system with patient sample being added to the assay tube  via transfer pipette.

2. Scan

Scan your assay tube using the built-in barcode scanner.

Read More
The Roche cobas® liat system scanning the assay tube using the built-in barcode scanner.

3. Start

Insert your assay tube into the cobas® liat analyzer.

Read More
Benefits at a glance

Benefits at a glance

cobas® liat benefit  icon quick
  • Multi- and single-target assays with results in minutes
  • Less than one minute of hands-on time
  • Intuitive, easy-to-use interface with step-by-step guided instruction
  • No operator intervention or interpretation
  • No laptops or additional equipment required
cobas® liat benefit icon confident
  • Gold standard PCR technology4-6
  • Reproducible4-6 results, wherever and whenever you need them
  • Accuracy at your fingertips, in all near-patient settings.
  • Designed for a fail-safe experience, the closed system reduces the risk of false results2-4
cobas® liat benefit icon control
  • On-demand downloading of assay scripts and core software
  • Supporting enhanced cybersecurity by eliminating USB file transfer
  • Streamlined updates across networks of devices
  • Maintenance informed by real-world instrument data

Overview

Ordering Information

error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later

Related products

A healthcare professional with a stethoscope sitting in front of her computer talks to

Targeting high-priority, curable STIs with definitive diagnosis at the Point of Care

Take control of your patients' sexual health by delivering quick, confident results where they're needed most. With the cobas® liat system, you can bring lab-quality PCR testing to the Point of Care, now including the cobas® liat CT/NG and cobas® liat CT/NG/MG assays for sexual health diagnostics.

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

Form Successfully Submitted!
Thank you for your submission!
text

*Turnaround times vary by assay

Emergency Use Authorization. The cobas® liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;

This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), not for any other viruses or pathogens; and

The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

References:

  1. Hansen GT et al. Clinical decision making in the emergency department setting using rapid PCR: Results of the CLADE study group. J Clin Virol. 2018;102:42-49. 
  2. F. Hoffmann-La Roche Ltd. cobas® liat system, Software version 3.5, User Guide, Publication version
  3. F. Hoffmann-La Roche Ltd. cobas® Influenza A/B & RSV Test v5, 2020 (CE-IVD) and v1, 2021 (US-IVD), cobas® SARS-CoV-2 & Influenza A/B Test v2, 2020 (CE-IVD) and v2, 2020 (US-IVD)
  4. F. Hoffmann-La Roche Ltd. cobas® SARS-CoV-2 Test v1, 2021 (CE-IVD) and v2, 2022 (US-IVD),cobas® Strep A Test v4, 2020 (CE-IVD) and v2, 2017 (US-IVD), cobas® Cdiff Test v4, 2022 (CE-IVD) and v2, 2021 US-IVD)
  5. F. Hoffmann-La Roche Ltd. cobas® liat system, v11, 2022
  6. F. Hoffmann-La Roche Ltd. cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test, Package Insert V01, 2020
  7. F. Hoffmann-La Roche Ltd. cobas® Influenza A/B & RSV package insert, 2021
  8. F. Hoffmann-La Roche Ltd. cobas® SARS-CoV-2 Nucleic acid test for use on the cobas® liat system, Package Insert V03, 2023
  9. F. Hoffmann-La Roche Ltd. cobas® Strep A package insert V4, 2020